Novavax Achieves Profitability Through Strategic Pivot

Novavax reports a $440M net profit for 2025, driven by a 65% revenue surge to $1.1B and lucrative tech licensing deals with Pfizer and Sanofi.

Novavax has successfully transitioned to profitability, marking a significant financial turnaround. The biotechnology firm, after a prolonged period of losses, reported a substantial net profit for the 2025 fiscal year alongside a major surge in revenue. This shift is attributed to a strategic realignment, moving its focus beyond direct vaccine production toward forging lucrative technology licensing agreements.

Financial Performance and Strategic Drivers

The company closed fiscal 2025 with a net profit of $440 million, a stark contrast to the significant losses that characterized 2024. This result was powered by a 65% year-over-year revenue increase, with total sales climbing to $1.1 billion.

A cornerstone of this resurgence is the company's Matrix-M adjuvant technology. A recent licensing agreement with Pfizer not only guarantees Novavax an upfront payment of $30 million for the first quarter of 2026 but also includes potential milestone payments reaching up to $500 million, plus ongoing royalties. This deal highlights the growing industry value placed on Novavax's proprietary platform.

Furthermore, the collaboration with Sanofi is generating significant cash flow. In 2025 alone, milestone payments from this partnership contributed $225 million to Novavax's coffers. These payments are linked to the transfer of commercial responsibility for the Nuvaxovid COVID-19 vaccine to Sanofi, which was completed in the EU in October 2025 and in the U.S. during the fourth quarter.

Streamlined Operations and Future Guidance

Management has issued an optimistic outlook for the current year, raising its adjusted revenue forecast for 2026 to a range of $230 million to $270 million. This guidance deliberately excludes any future payments from the Sanofi partnership. Concurrently, Novavax is implementing rigorous cost-cutting measures, targeting a reduction in research and administrative expenses of approximately 50% by 2028 compared to 2025 levels.

To bolster its balance sheet, the company secured a $330 million credit facility. This financing provides access to capital without the need to issue new shares, thereby preventing dilution for existing shareholders. Investor confidence is evident in the equity's performance: the share price has advanced roughly 55% since the start of the year, recently trading at a new 52-week high of €9.49.

Despite this operational momentum, company leadership noted that vaccine manufacturers in the U.S. continue to face a challenging regulatory landscape. Nevertheless, the concluded fiscal year represents a pivotal transformation for Novavax from a loss-making biotech entity to a profitable technology partner for global pharmaceutical giants.